Research Peptides
Maple Research Labs supplies high-purity research peptides manufactured in Canada. Products are independently tested by a third-party laboratory, with Certificates of Analysis (COA) available for verified batches. Our peptides are intended strictly for in-vitro research and laboratory use.
HPLC-Verified Purity
3rd Party COA Testing
Canadian Shipping
-

BPC-157 + TB-500 Blend
$139.00
Read more Read more
-

BPC-157 10MG
$75.00
Add to cart Add to cart
-

CJC-1295 (No DAC)
$60.00
Add to cart Add to cart
-

CJC-1295 DAC
$63.00
Add to cart Add to cart
-

GHK-Cu 50MG
$55.00
Add to cart Add to cart
-

Melanotan 1 10MG
$50.00
Add to cart Add to cart
-

MOTS-C 10MG
$49.00
Add to cart Add to cart
-

PT-141
$50.00
Read more Read more
-

Selank
$70.00
Add to cart Add to cart
-

Semax
$70.00
Add to cart Add to cart
-

TB-500 5MG
$85.00
Add to cart Add to cart
Research Use Disclaimer
All products sold by Maple Research Labs are intended for research purposes only. They are not for human consumption, diagnostic use, or therapeutic application. By purchasing, you confirm that you are a qualified researcher or buyer and that the products will be used in accordance with all applicable regulations.
Research Deep-Dives by Compound
Mechanism of action summaries, published study citations, and research context for each compound category.
Comprehensive overview: peptide synthesis, purity testing, storage, major research categories, and supplier evaluation. Start here.
Retatrutide, tirzepatide, semaglutide. Single vs dual vs triple agonism.
Cytoprotection, angiogenesis, NO system modulation.
Actin regulation, wound healing, tissue remodeling.
Gene expression modulation, collagen synthesis, ECM regulation.
Selective GHS-R1a agonism, GH release specificity.
DAC vs No DAC, pulsatile vs tonic GH release.
ACTH(4-10) analogue, BDNF/TrkB modulation.
Tuftsin-derived, GABAergic and enkephalinergic modulation.
AMPK activation, exercise mimetic mechanisms.
Modified GHRH(1-44), FDA-approved (Egrifta), VAT and IGF-1 axis research.
MT-I vs MT-II, MC1R-MC5R receptor pharmacology, EMA-approved analogue.
MC4R agonism, CNS-mediated signaling, FDA-approved (Vyleesi).
Sirtuin/PARP substrate, age-related decline, NMN/NR precursor research.
Imbalanced dual agonism, biased GLP-1R signaling, SURPASS trials.
GIP + GLP-1 + glucagon receptor, energy expenditure axis.
Selective GLP-1R agonist, the benchmark for incretin research.
CJC-1295 DAC vs No DAC vs Ipamorelin vs Tesamorelin.
BDNF/neurotrophic vs GABAergic/enkephalinergic neuropeptides.
Cytoprotection/angiogenesis vs actin-mediated cell migration.
MC1R vs MC4R selectivity, linear vs cyclic melanocortin analogues.
Maple 













